Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11526542 | 0.80 | KMT2A (0.59) | APOBEC3GKMT2AHSD11B1TSHRSMN1; SMN2 | |
| SCHEMBL7924261 | 0.79 | APOBEC3G (0.50) | APOBEC3GKMT2AHSD11B1CA12CA1 | |
| SCHEMBL11034530 | 0.79 | APOBEC3G (0.50) | APOBEC3GKMT2AHSD11B1CA12CA1 | |
| SCHEMBL11524385 | 0.78 | HSD11B1 (0.62) | APOBEC3GKMT2AHSD11B1TSHRSMN1; SMN2 | |
| SCHEMBL8579922 | 0.78 | APOBEC3G (0.48) | APOBEC3GKMT2AHSD11B1CA12CA1 | |
| SCHEMBL728027 | 0.78 | APOBEC3G (0.48) | APOBEC3GKMT2AHSD11B1CA12CA1 | |
| SCHEMBL3069669 | 0.78 | APOBEC3G (0.48) | APOBEC3GKMT2AHSD11B1CA12CA1 | |
| SCHEMBL27540835 | 0.76 | HSD11B1 (0.65) | APOBEC3GKMT2AHSD11B1CA12CA9 | |
| SCHEMBL30244490 | 0.74 | APOBEC3G (0.45) | APOBEC3GKMT2AHSD11B1CA12CA1 | |
| SCHEMBL174224 | 0.74 | KMT2A (0.62) | APOBEC3GKMT2AHSD11B1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2017-10-19 | — | — | US | disclosed |
| US-9738599-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-22 | — | — | US | disclosed |
| US-9718781-B2 | Methods and compounds for treating proliferative disorders and viral infections | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-08-01 | — | — | US | disclosed |
| US-20170183300-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2017-06-29 | — | — | US | disclosed |
| US-9630915-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-04-25 | — | — | US | disclosed |
| US-20170057913-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-9522877-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-12-20 | — | — | US | disclosed |
| US-20160280640-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2016-09-29 | — | — | US | disclosed |
| US-20160102051-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | ATXA THERAPEUTICS LIMITED (IE) | 2016-04-14 | — | — | US | disclosed |
| EP-2838519-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2838520-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156871-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013156861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102051-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | TBXA2R, PTGFR, TBXAS1 | APOBEC3G 2159/4885KMT2A 1962/4885HSD11B1 1534/4885 |
| US-20170298020-A1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | TBXA2R, PTGFR, TBXAS1 | APOBEC3G 2159/4885KMT2A 1962/4885HSD11B1 1534/4885 |
| US-20170183300-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, TBXAS1, PTGIR | APOBEC3G 3584/4885KMT2A 2845/4885HSD11B1 3016/4885 |
| US-20170057913-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, TBXAS1, PTGIR | APOBEC3G 3584/4885KMT2A 2845/4885HSD11B1 3016/4885 |
| US-20160280640-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, TBXAS1, PTGIR | APOBEC3G 3584/4885KMT2A 2845/4885HSD11B1 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.